Protein Hydrolysis Targeted Chimeras (PROTAC) are bringing revolutionary changes to the fields of biology and medicinal chemistry. PROTAC consists of a target protein ligand, an E3 ligase ligand, and a spacer group[Unlike the linker used in antibody-drug conjugates, here we specifically use “spacer” instead of the commonly seen “linker” in PROTAC literature]. PROTAC structural composition … Read more
To deliver chemotherapy drugs more effectively, small molecule drug conjugates (SMDC), antibody-drug conjugates (ADC), and degrader-antibody conjugates (DAC) have been explored and developed, providing selective delivery while improving the therapeutic index. What are their similarities and differences? What are their respective advantages? What is the current state of research? What does the future hold? This … Read more
Recently, ADC (Antibody-Drug Conjugate) conferences have been held one after another, with major biotech companies competing to report their ADC pipelines. It is expected that 2024 will still be the main venue for ADCs. Developing an entry-level ADC seems not difficult, but evaluating the pharmacology and toxicology in the preclinical stage has become a top … Read more
Introduction Antibody-drug conjugates (ADC) are comprised of monoclonal antibodies that target specific antigens linked to small molecule cytotoxic drugs via a linker, combining the powerful killing effects of traditional small molecule chemotherapy with the tumor-targeting properties of antibody drugs. Since the first ADC (Gemtuzumab-ozogamicin (trade name: Mylotarg)) was approved for the treatment of CD33-positive acute … Read more
Introduction Antibody-drug conjugates (ADC) combine the high specificity of monoclonal antibodies with the high potency of small molecule cytotoxic drugs to enhance the targeting of cancer therapies and reduce side effects. Compared to traditional antibodies or antibody fragments, ADCs can release highly active cytotoxins within tumor tissues, theoretically leading to higher efficacy. ADCs have undergone … Read more
Key Content Preview:In recent years, antibody-drug conjugates (ADCs) have developed rapidly. As of August 2023, there are a total of 15 ADCs on the market globally, with over 1200 drugs under research. In June this year, Nature Biotechnology published a brief report titled “ADCs’ Revival”, highlighting the “breakthrough momentum” of ADCs in new drug development. … Read more
By | Little Medicine Monster Global ADC Pipeline Status As of December 6, 2023, a total of 1166 ADC pipelines have been developed globally, with 524 pipelines under research and 16 approved drugs (including two TDM-1 biosimilars). The abandonment rate of pipelines is as high as 54% (1166-524-16/1166). Among the 524 pipelines under research, over … Read more
Introduction Antibody-drug conjugates (ADC) are formed by linking monoclonal antibodies targeting specific antigens with small molecule cytotoxic drugs through linkers, combining the powerful killing effect of traditional small molecule chemotherapy with the tumor targeting ability of antibody drugs. Since ADCs first entered clinical trials in the mid-1990s, they have developed into a very successful oncology … Read more
Antibody-drug conjugates (ADC) have become one of the most sought-after methods for treating cancer patients. Recently, several notable deals have taken place between small biotech companies developing ADCs and large companies looking to enhance their oncology pipelines. The recent Kangfang AK112 incident has brought bispecific antibodies into the spotlight, with some discussing the viability of … Read more
Compiled by: Oncology Information Source: Oncology Information Antibody-drug conjugates (ADCs) are formed by linking monoclonal antibodies that target specific antigens with cytotoxic small molecule drugs, combining the targeting specificity of antibody drugs with the powerful lethality of cytotoxins. The aim is to overcome the issues of weak cytotoxicity of monoclonal antibodies and the high toxicity … Read more